<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673153</url>
  </required_header>
  <id_info>
    <org_study_id>2200.00</org_study_id>
    <secondary_id>NCI-2010-00401</secondary_id>
    <nct_id>NCT00673153</nct_id>
  </id_info>
  <brief_title>Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia</brief_title>
  <official_title>Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid or SAHA; Zolinza™) in Combination With Gemtuzumab Ozogamicin (Mylotarg™) as Induction and Post-Remission Therapy in Older Patients With Previously Untreated Non-M3 Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vorinostat may stop the growth of cancer cells by interfering with various
      proteins needed for cell growth. Monoclonal antibodies, such as gemtuzumab ozogamicin (GO),
      can block cancer growth in different ways. GO finds cancer cells and helps kill them by
      carrying a cancer-killing substance to them. Giving vorinostat together with gemtuzumab
      ozogamicin may kill more cancer cells.

      PURPOSE: This phase II trial is studying how well giving vorinostat together with gemtuzumab
      ozogamicin works in treating older patients with previously untreated acute myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the CR/CRi rate after treatment with vorinostat plus GO. (Good risk group)
      II. To determine the 30-day survival after treatment with vorinostat plus GO. (Poor risk
      group)

      SECONDARY OBJECTIVES:

      I. To estimate the frequency and severity of regimen-associated toxicities, along with 30-day
      survival after start of treatment with vorinostat plus GO. (Good risk group) II. To determine
      the CR/CRi rate after treatment with vorinostat plus GO, and estimate the frequency and
      severity of regimen-associated toxicities. (Poor risk group) III. To investigate the
      relapse-free survival of patients who achieve CR/CRi and receive maintenance therapy on this
      study.

      IV. To define cellular factors associated with clinical response to GO/vorinostat and
      determine the mechanisms underlying the synergistic effect between GO and vorinostat on
      primary AML cells (in vitro correlative and mechanistic studies).

      OUTLINE:

      REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and
      gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to
      3 courses.

      CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction
      therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV
      over 2 hours on day 8.

      MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment
      repeats every 28 days for 4 courses.

      All treatment continues in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for up to 3
      years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 2008</start_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Achieving CR or CRi With Induction Therapy (Good-risk Group)</measure>
    <time_frame>after completion of induction therapy, administered every 21-42 days for up to two courses</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Alive at Day 30 (Poor-risk Group)</measure>
    <time_frame>At day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free Survival (Good- and Poor-risk Group)</measure>
    <time_frame>At relapse</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving CR or CRi With Induction Therapy (Poor-risk Group)</measure>
    <time_frame>after completion of induction therapy, administered every 21-42 days for up to two courses</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Alive at Day 30 (Good-risk Group)</measure>
    <time_frame>At day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Adult Acute Megakaryoblastic Leukemia (M7)</condition>
  <condition>Adult Acute Minimally Differentiated Myeloid Leukemia (M0)</condition>
  <condition>Adult Acute Monoblastic Leukemia (M5a)</condition>
  <condition>Adult Acute Monocytic Leukemia (M5b)</condition>
  <condition>Adult Acute Myeloblastic Leukemia With Maturation (M2)</condition>
  <condition>Adult Acute Myeloblastic Leukemia Without Maturation (M1)</condition>
  <condition>Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities</condition>
  <condition>Adult Acute Myeloid Leukemia With Del(5q)</condition>
  <condition>Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)</condition>
  <condition>Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)</condition>
  <condition>Adult Acute Myelomonocytic Leukemia (M4)</condition>
  <condition>Adult Erythroleukemia (M6a)</condition>
  <condition>Adult Pure Erythroid Leukemia (M6b)</condition>
  <condition>Untreated Adult Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .
CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.
MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemtuzumab ozogamicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody</other_name>
    <other_name>CDP-771</other_name>
    <other_name>CMA-676</other_name>
    <other_name>hP67.6-Calicheamicin</other_name>
    <other_name>Mylotarg</other_name>
    <other_name>WAY-CMA-676</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>L-001079038</other_name>
    <other_name>SAHA</other_name>
    <other_name>suberoylanilide hydroxamic acid</other_name>
    <other_name>Zolinza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Morphological diagnosis of AML other then acute promyelocytic leukemia (FAB M3)
             according to WHO diagnostic criteria; diagnosis of AML must be based on bone marrow or
             peripheral blood studies obtained within 28 days prior to study registration or start
             of hydroxyurea (for patients presenting with WBC &gt;= 10,000/uL), and no potentially
             anti-leukemic therapy (with the exception of hydroxyurea) must have been given between
             AML diagnosis and study registration; a bone marrow biopsy is not routinely required
             but should be obtained if the aspirate is dilute, hypocellular, or inaspirable;
             outside bone marrows performed within the stipulated time period are acceptable as
             long as the slides are reviewed at a study institution

          -  Cytogenetic analysis on bone marrow or peripheral blood specimen is available; based
             on the result from the first interim analysis, patients stratified into the good-risk
             group are only eligible if their AML has favorable cytogenetics (core-binding factor
             AML) or has a normal karyotype; patients stratified into the poor-risk group are
             eligible independent of the cytogenetic analysis

          -  Pretreatment bone marrow and peripheral blood specimens for correlative studies are
             available; if bone marrow was performed at an outside facility, submission of
             peripheral blood only is acceptable as long as the peripheral blast count is &gt;
             5,000/uL and &gt; 50% of total WBC

          -  Patients with a history of antecedent MDS are eligible, if prior treatment did not
             include intensive chemotherapy; patients may have received hematopoietic growth
             factors, thalidomide/lenalidomide, 5-azacytidine/decitabine, arsenic trioxide, signal
             transduction inhibitors, or low dose cytarabine (&lt; 100 mg/m2/day) for treatment of
             MDS; patients must be off prior therapy for MDS at least 30 days prior to study
             registration, and all non-hematologic toxicities must have resolved to &lt; grade 2

          -  ECOG/WHO/Zubrod performance status of 0-3

          -  Bilirubin =&lt; 2.5 x Institutional Upper Limit of Normal (IULN) unless elevation is
             thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis
             (assessed within 14 days prior to registration)

          -  SGOT (AST) and SPGT (ALT) =&lt; 1.5 x IULN unless elevation is thought to be due to
             hepatic infiltration by AML (assessed within 14 days prior to registration)

          -  Serum creatinine =&lt; 1.5 x IULN (assessed within 14 days prior to registration)

          -  Left ventricular ejection fraction &gt;= 40% and no clinical evidence of congestive heart
             failure (assessed within 28 days prior to registration, e.g. by MUGA scan or
             echocardiography)

          -  Men of reproductive potential must use an effective contraceptive method throughout
             the study and for a period of at least 3 months after the study

          -  Women must be postmenopausal; a postmenopausal woman is defined as a woman who has
             experienced amenorrhea &gt; 12 consecutive months or a woman on hormone replacement
             therapy with documented FSH level &gt; 35 mIU/mL (women of childbearing potential must
             have a pregnancy test within 28 days prior to registration, and must use an adequate
             method of contraception to avoid pregnancy throughout the study and for a period of at
             least 3 months after the study)

          -  Provide signed written informed consent

          -  Willingness to undergo bone marrow examination on day 8 of first induction cycle

          -  WBC &lt; 10,000/uL (patients with WBC &gt;= 10,000/uL must undergo cytoreduction with
             hydroxyurea prior to enrollment and will not be enrolled if the WBC remains &gt;=
             10,000/uL (of note, patients with symptoms/signs of hyperleukocytosis or WBC &gt;
             100,000/uL can be treated with leukapheresis prior to enrollment)

        Exclusion Criteria:

          -  Diagnosis of another malignancy, unless the patient was diagnosed at least 2 years
             earlier and has been disease-free for at least 6 months following the completion of
             curative intent therapy; there should be no plan to begin therapy for the prior
             malignancy at the time of study registration; prior treatment with AML induction-type
             chemotherapy is not allowed (note the following exceptions: patients with treated
             non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia,
             regardless of the disease-free duration, are eligible for this study if definitive
             treatment for the condition has been completed; patients with organ-confined prostate
             cancer with no evidence of recurrent or progressive disease based on prostate-specific
             antigen [PSA] values are also eligible for this study if hormonal therapy has been
             initiated or a radical prostatectomy has been performed; concurrent hormonal therapy
             is allowed)

          -  Myeloid blast crisis of chronic myelogenous leukemia (CML)

          -  Prior systemic chemotherapy for AML with the exception of hydroxyurea

          -  Prior treatment with AML induction-type chemotherapy, GO, HDAC inhibitors, or high
             dose chemotherapy with hematopoietic stem cell support

          -  Treatment with HDAC inhibitors during the last 3 years prior to registration,
             including the use of valproic acid for seizure activity or other purposes

          -  Known hypersensitivity to hydroxyurea, GO, or vorinostat

          -  Clinical evidence suggestive of central nervous system (CNS) involvement with leukemia
             unless a lumbar puncture confirms the absence of leukemic blasts in the cerebrospinal
             fluid (CSF)

          -  Prior positive test for the human immunodeficiency virus (HIV)

          -  Breastfeeding

          -  Uncontrolled systemic fungal, bacterial, viral, or other infection (defined as
             exhibiting ongoing signs/symptoms related to the infection and without improvement,
             despite appropriate antibiotics or other treatment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Walter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2008</study_first_submitted>
  <study_first_submitted_qc>May 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <results_first_submitted>March 15, 2017</results_first_submitted>
  <results_first_submitted_qc>May 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2017</results_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fred Hutchinson Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Roland Walter</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Monocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Megakaryoblastic, Acute</mesh_term>
    <mesh_term>Leukemia, Erythroblastic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .
CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.
MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses.
gemtuzumab ozogamicin: Given IV
vorinostat: Given orally
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .
CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.
MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses.
gemtuzumab ozogamicin: Given IV
vorinostat: Given orally
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" lower_limit="61" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk Group</title>
          <description>Poor-risk Group: patients aged ≥70 years and performance status 2-3; Good-risk Group: aged 60-69 years with performance status 0-3, or aged ≥70 years and performance status 0-1
Performance status based on Eastern Cooperative Oncology Group's scale, abbreviated below:
0 Fully active
Restricted in strenuous activity but capable of a light or sedentary work activities,
Ambulatory and capable of all selfcare but unable to carry out any work activities;
Capable of only limited selfcare;
Completely disabled; cannot carry on any selfcare; confined to bed or chair
Dead</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Poor-risk Group</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Good-risk Group</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving CR or CRi With Induction Therapy (Good-risk Group)</title>
        <time_frame>after completion of induction therapy, administered every 21-42 days for up to two courses</time_frame>
        <population>Good-risk Group: aged 60-69 years with performance status 0-3, or aged ≥70 years and performance status 0-1</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .
CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.
MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses.
gemtuzumab ozogamicin: Given IV
vorinostat: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving CR or CRi With Induction Therapy (Good-risk Group)</title>
          <population>Good-risk Group: aged 60-69 years with performance status 0-3, or aged ≥70 years and performance status 0-1</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Alive at Day 30 (Poor-risk Group)</title>
        <time_frame>At day 30</time_frame>
        <population>Poor-risk Group: patients aged ≥70 years and performance status 2-3</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .
CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.
MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses.
gemtuzumab ozogamicin: Given IV
vorinostat: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Alive at Day 30 (Poor-risk Group)</title>
          <population>Poor-risk Group: patients aged ≥70 years and performance status 2-3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse-free Survival (Good- and Poor-risk Group)</title>
        <time_frame>At relapse</time_frame>
        <population>Poor-risk Group: patients aged ≥70 years and performance status 2-3; Good-risk Group: aged 60-69 years with performance status 0-3, or aged ≥70 years and performance status 0-1</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .
CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.
MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses.
gemtuzumab ozogamicin: Given IV
vorinostat: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse-free Survival (Good- and Poor-risk Group)</title>
          <population>Poor-risk Group: patients aged ≥70 years and performance status 2-3; Good-risk Group: aged 60-69 years with performance status 0-3, or aged ≥70 years and performance status 0-1</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving CR or CRi With Induction Therapy (Poor-risk Group)</title>
        <time_frame>after completion of induction therapy, administered every 21-42 days for up to two courses</time_frame>
        <population>Poor-risk Group: patients aged ≥70 years and performance status 2-3</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .
CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.
MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses.
gemtuzumab ozogamicin: Given IV
vorinostat: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving CR or CRi With Induction Therapy (Poor-risk Group)</title>
          <population>Poor-risk Group: patients aged ≥70 years and performance status 2-3</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Alive at Day 30 (Good-risk Group)</title>
        <time_frame>At day 30</time_frame>
        <population>Good-risk Group: aged 60-69 years with performance status 0-3, or aged ≥70 years and performance status 0-1</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .
CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.
MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses.
gemtuzumab ozogamicin: Given IV
vorinostat: Given orally
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Alive at Day 30 (Good-risk Group)</title>
          <population>Good-risk Group: aged 60-69 years with performance status 0-3, or aged ≥70 years and performance status 0-1</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>REMISSION INDUCTION THERAPY: Patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8. Treatment repeats every 15-22 days for up to 3 courses. .
CONSOLIDATION THERAPY: Beginning within 60 days after the completion of remission induction therapy, patients receive oral vorinostat once daily on days 1-9 and gemtuzumab ozogamicin IV over 2 hours on day 8.
MAINTENANCE THERAPY: Patients receive oral vorinostat once daily on days 1-14. Treatment repeats every 28 days for 4 courses.
gemtuzumab ozogamicin: Given IV
vorinostat: Given orally
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>E-coli Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Perirectal cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bleeding at PICC site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hemorrhage, post bone marrow</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Non-ST-elevation myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Bleed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Appendix Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Edema/Swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Streptococcus salivarius</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Bacteremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Increased lactate dehydrogenase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diaphoresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Nodules</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma, scalp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days from the time submitted to the sponsor for review. The sponsor CAN require changes to the communication and CAN extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roland B. Walter, MD, PhD, MS</name_or_title>
      <organization>Fred Hutch Cancer Research Center</organization>
      <phone>(206) 667-3599</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

